ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1569

Optimizing Care for Patients with Rheumatoid Arthritis Newly Treated with Biologics by Evaluating Health Status with AIMS-2

Mie Fusama1, Hideko Nakahara2, Keisuke Kawamoto3, Satoko Nozato3, Midori Taguchi3, Kohji Nishioka3, Shinji Higa3, Eiji Takeuchi4, Kayoko Higashi5, Masao Yukioka6, Tsuyoshi Igarashi3, Taro Kuritani3, Keiji Maeda3 and Yasushi Miura7, 1Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, 2Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, 3Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, 4Department of Orthopaedic Surgery, NTT West Osaka Hospital, Osaka, Japan, 5Division of nursing, NTT West Osaka Hospital, Osaka, Japan, 6Department of Orthopaedic Surgery, Yukioka Hospital, Osaka, Japan, 7Department of Rehabilitation Science, Graduate School of Health Sciences, Kobe University, Kobe, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: biologic response modifiers, Health education, quality of life, rheumatoid arthritis (RA) and social support

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Clinical Practice/Patient Care

Session Type: Abstract Submissions (ARHP)

Background/Purpose:

Biologics significantly improve disease activity of rheumatoid arthritis (RA), however, patient global assessment (PGA) is not always improved in parallel with disease activity scores. Though the 2011 ACR/EULAR definitions of remission criteria for RA adopt Boolean-based definition, there are few reports analyzing health status and patient satisfaction in the view of PGA for patients with RA treated with biologics.

To assess the correlation between each component of health status including patient satisfaction and Boolean-based definition of PGA remission for RA, patients newly treated with biologics were investigated for 24 weeks.

Methods: Patients with RA treated with 8 mg/kg of tocilizumab (TCZ) every 4 weeks, 3mg/kg of infliximab (IFX) at 0, 2, 6 weeks and thereafter every 8 weeks, 25mg of etanercept (ETN) twice a week were participated in this study. Health status with Arthritis Impact Measurement Scale 2 (AIMS-2), disease activity scores (tender joint count (TJC), swollen joint count (SJC), PGA and evaluator global assessment (EGA) on visual analogue scale (VAS), DAS28-CRP, SDAI, and CDAI) were assessed at week 0 and week 24. Comparison analysis of health status was performed between the patients who achieved the remission criteria of PGA (PGA�=<1cm) and those who did not. The data analysis was performed utilizing Wilcoxon rank sum test.

Results:

Sixty-six patients newly treated with biologics (TCZ: 39, IFX: 16, ETN: 11) were participated. Baseline characteristics were as follows: mean±SD of age (54.6±11.7 years), duration (6.7±7.2 years), SJC (10.9±7.5), TJC (10.8±6.1), PGA (5.4±2.4cm), EGA (5.5±2.1cm), CRP (2.4±2.6mg/dl), DAS28-CRP (5.3±1.3), SDAI (35.0±15.9), and CDAI (33.0±14.7), respectively. Twenty-seven of 66 patients (40.9%) achieved PGA remission. At baseline, there were no significant differences in age, duration, SJC, TJC, PGA, EGA, CRP, DAS28, SDAI, CDAI, or components of AIMS-2 between PGA remission and non-remission groups. At week 24, SJC, TJC, EGA, DAS28-CRP, SDAI, and CDAI were significantly lower in PGA remission group. At week 24, among health status, physical function, symptom, and role of AIMS-2 were significantly improved in PGA remission group compared with non-remission group. At week 24, patient satisfactory scores were significantly improved in PGA remission group except social interaction. Only the patient satisfactory scores for household and role (work) were significantly higher in PGA remission group compared with non-remission group at baseline.

Conclusion:

For the patients with lower satisfactory scores in household and role (work) of health status at baseline, it is considered difficult to achieve PGA remission even when treated with biologics. Social interaction is not improved even when PGA remission is achieved. Therefore, nurses caring patients with RA are expected to assist patients to understand the importance of early treatment, support social activity, and set proper goal of treatment by evaluating health status.


Disclosure:

M. Fusama,
None;

H. Nakahara,
None;

K. Kawamoto,
None;

S. Nozato,
None;

M. Taguchi,
None;

K. Nishioka,
None;

S. Higa,
None;

E. Takeuchi,
None;

K. Higashi,
None;

M. Yukioka,
None;

T. Igarashi,
None;

T. Kuritani,
None;

K. Maeda,
None;

Y. Miura,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/optimizing-care-for-patients-with-rheumatoid-arthritis-newly-treated-with-biologics-by-evaluating-health-status-with-aims-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology